ResearcherEge UniversityNo recent work listed

Elvina Almuradova

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5551-7731; OpenAlex author ID A5058277753. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper

Papers 1

Metastatic Pancreatic Cancer Second-Line Treatment Options: Is the Difference Only in Cost? Last author DOI 10.1007/s12029-020-00573-y ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Gülcan Bulut · 1 shared paper, 2022 · strength 0.16
- Paper Metastatic Pancreatic Cancer Second-Line Treatment Options: Is the Difference Only in Cost? DOI 10.1007/s12029-020-00573-y ↗
Serkan Yıldırım · 1 shared paper, 2022 · strength 0.16
- Paper Metastatic Pancreatic Cancer Second-Line Treatment Options: Is the Difference Only in Cost? DOI 10.1007/s12029-020-00573-y ↗
Ferhat Ekinci · 1 shared paper, 2022 · strength 0.16
- Paper Metastatic Pancreatic Cancer Second-Line Treatment Options: Is the Difference Only in Cost? DOI 10.1007/s12029-020-00573-y ↗
Atike Pınar Erdoğan · 1 shared paper, 2022 · strength 0.16
- Paper Metastatic Pancreatic Cancer Second-Line Treatment Options: Is the Difference Only in Cost? DOI 10.1007/s12029-020-00573-y ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.